Trial Profile
A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2021
Price :
$35
*
At a glance
- Drugs Ciclesonide (Primary) ; Hydroxychloroquine (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- 19 Jun 2021 Status changed from recruiting to completed.
- 04 Feb 2021 Planned number of patients changed from 141 to 66.
- 04 Feb 2021 Planned End Date changed from 31 Dec 2020 to 31 Mar 2021.